Literature DB >> 33857528

Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms.

Yifei Xie1, Ke Yao2, Zigang Dong3, Kangdong Liu4.   

Abstract

Proliferating cancer cells exhibit metabolic alterations and specific nutritional needs for adapting to their rapid growth. These changes include using aerobic glycolysis, lipid metabolic disorder, and irregular protein degradation. It may be useful to target metabolic abnormalities for cancer chemoprevention. Epidemiological and mechanism-related studies have indicated that many FDA-approved anti-metabolic drugs decrease tumor risk, inhibit tumor growth, or enhance the effect of chemotherapeutic drugs. Drugs targeting nutrient metabolism have fewer side effects with long-term use compared to chemotherapeutic drugs. The characteristics of these drugs make them promising candidates for cancer chemoprevention. Here, we summarize recent discoveries of the chemo-preventive effects of drugs targeting nutrient metabolic pathways and discuss future applications and challenges. Understanding the effects and mechanisms of anti-metabolic drugs in cancer has important implications for exploring strategies for cancer chemoprevention.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer chemoprevention; FDA-Approved drugs; Nutrient metabolism

Mesh:

Year:  2021        PMID: 33857528     DOI: 10.1016/j.canlet.2021.03.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

Review 1.  Boron-Containing Compounds for Prevention, Diagnosis, and Treatment of Human Metabolic Disorders.

Authors:  Córdova-Chávez Ri; Carrasco-Ruiz Mf; Rodríguez-Vera D; Pérez-Capistran T; Tamay-Cach F; Scorei Ir; Abad-García A; Soriano-Ursúa Ma
Journal:  Biol Trace Elem Res       Date:  2022-06-30       Impact factor: 3.738

2.  Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy.

Authors:  Xiao Li; Liangliang Wu; Zhiying Zheng; Hanyuan Liu; Haiyang Li; Guoqiang Sun; Guangshun Sun; Ye Cheng; Hanjin Wang; Zhouxiao Li; Junfeng Shi; Weiwei Tang
Journal:  J Oncol       Date:  2022-02-03       Impact factor: 4.375

3.  Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2.

Authors:  Zitong Wang; Yingying Chen; Xiaoyu Li; Yuhan Zhang; Xiaokun Zhao; Hao Zhou; Xuebo Lu; Lili Zhao; Qiang Yuan; Yunshu Shi; Jimin Zhao; Ziming Dong; Yanan Jiang; Kangdong Liu
Journal:  Cancers (Basel)       Date:  2022-07-23       Impact factor: 6.575

4.  Arbidol inhibits human esophageal squamous cell carcinoma growth in vitro and in vivo through suppressing ataxia telangiectasia and Rad3-related protein kinase.

Authors:  Ning Yang; Xuebo Lu; Yanan Jiang; Lili Zhao; Donghao Wang; Yaxing Wei; Yin Yu; Myoung Ok Kim; Kyle Vaughn Laster; Xin Li; Baoyin Yuan; Zigang Dong; Kangdong Liu
Journal:  Elife       Date:  2022-09-09       Impact factor: 8.713

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.